Calidi Biotherapeutics closes public offering, raising $7.5 million

From GlobeNewswire: 2024-11-15 16:05:00

Calidi Biotherapeutics Inc. announced the closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising $7.5 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering. The offering was made pursuant to registration statements on Form S-3, declared effective by the SEC. Calidi Biotherapeutics is a clinical-stage immuno-oncology company developing antitumor virotherapies. Their technology uses stem cells to deliver oncolytic viruses for treating high-grade gliomas and solid tumors. The company’s goal is to enhance efficacy and improve patient safety in cancer treatment. For more information, visit www.calidibio.com.



Read more at GlobeNewswire: Calidi Biotherapeutics Announces Closing of $7.5 Million